Company intelligence / Profile preview

StemGenex

San Diego, California, United Statesstemgenex.com ↗

Ownership: Private
Development stage: Other

Overview

StemGenex marketed an unapproved autologous adipose-derived stromal vascular fraction product for multiple serious diseases without FDA approval. The company did not have any INDs or posted clinical trial results demonstrating efficacy, and its products were subject to significant regulatory warnings due to manufacturing violations and lack of safety/efficacy data.

Therapeutic areas: NeurologyPulmonologyGastroenterologyEndocrinologyImmunologyRheumatology
Modalities: Stem cell therapy (specifically autologous adipose-derived stromal vascular fraction)
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on StemGenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemGenex.

Explore the full profile